Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer

Br J Urol. 1987 Mar;59(3):248-54. doi: 10.1111/j.1464-410x.1987.tb04616.x.


One hundred and four patients were randomised for the study. Fifty-five were entered into the D-Trp-6-LHRH group and 49 into the orchiectomy group. All pre-treatment patient characteristics were similar and testosterone levels at 1 month or later were in the castrate range in both groups. Forty-six patients (83%) in the D-Trp-6-LHRH group and 40 (82%) in the orchiectomy group had a partial remission or stable disease at 3 months or later. There was no significant difference between the groups for response or survival. Three patients in the D-Trp-6-LHRH group had a disease "flare" in the first 10 days of treatment. The flare symptoms resolved by the end of 4 to 8 weeks. The incidence of flushing, decreased libido and impotence was similar in both groups. Although there was less psychological morbidity in the D-Trp-6-LHRH group the difference did not reach statistical significance. Our results indicate that long-acting D-Trp-6-LHRH offers a safe and highly effective alternative to orchiectomy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic
  • Delayed-Action Preparations
  • Gonadotropin-Releasing Hormone / adverse effects
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Male
  • Neoplasm Metastasis
  • Orchiectomy* / adverse effects
  • Pain
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / surgery
  • Prostatic Neoplasms / therapy*
  • Random Allocation
  • Triptorelin Pamoate
  • Urination Disorders / complications


  • Delayed-Action Preparations
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone